{"id":"masked-ikervis","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation/burning"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Foreign body sensation"},{"rate":null,"effect":"Blurred vision"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclosporine is a calcineurin inhibitor that reduces T-cell activation and pro-inflammatory cytokine production in the eye. By decreasing ocular surface inflammation, it addresses the underlying immune dysfunction in dry eye disease, particularly in cases with significant inflammatory component.","oneSentence":"Ikervis is a cyclosporine A ophthalmic emulsion that suppresses local immune-mediated inflammation in the ocular surface.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:12.143Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease with significant inflammatory component"}]},"trialDetails":[{"nctId":"NCT04144413","phase":"PHASE3","title":"3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2019-05-31","conditions":"Dry Eye Disease With Severe Keratitis","enrollment":350}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Masked Ikervis","genericName":"Masked Ikervis","companyName":"Santen SAS","companyId":"santen-sas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ikervis is a cyclosporine A ophthalmic emulsion that suppresses local immune-mediated inflammation in the ocular surface. Used for Dry eye disease with significant inflammatory component.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}